银屑病关节炎与中轴型脊柱关节炎患者接受生物或靶向改善病情药物治疗后感染发生率:随机对照试验、开放标签研究与观察性研究的系统评价与Meta分析
该系统评价与Meta分析纳入23333例银屑病关节炎(PsA)和11457例中轴型脊柱关节炎(axSpA)患者,评估接受肿瘤坏死因子抑制剂、白细胞介素-17抑制剂、Janus激酶抑制剂、IL-23或IL-12/23抑制剂、磷酸二酯酶4抑制剂或细胞毒性T淋巴细胞相关蛋白4-Ig治疗后的感染发生率。严重感染总发生率为每100患者年1.09例(95%CI 0.85至1.35),PsA为0.96(95%CI 0.69至1.28),axSpA为1.09(95%CI 0.76至1.46);随机对照试验中严重感染发生率(0.77每100患者年,95%CI 0.41至1.20)低于观察性研究(1.68每100患者年,95%CI 1.03至2.47)。非严重感染在随机对照试验中更常见(69.95每100患者年,95%CI 61.59至78.84),观察性研究为15.37每100患者年(95%CI 5.11至30.97)。
要点
- 严重感染在随机对照试验和真实世界研究中均为罕见事件。
- 非严重感染是常见不良事件,主要见于随机对照试验。
- PsA患者中IL-12/23抑制剂严重感染发生率最低(0.29每100患者年,95%CI 0.00至1.03)。
核心结论
- 严重感染在随机对照试验和真实生活研究中均为罕见事件,非严重感染是常见不良事件,主要见于随机对照试验。
研究设计与样本
- 对随机对照试验、开放标签扩展研究和观察性研究进行的Meta分析,采用随机效应模型计算95%CI。
- 共纳入23333例PsA患者和11457例axSpA患者。
- 严重感染定义为危及生命、需要静脉抗生素和/或住院治疗的感染;非严重感染不符合上述严重度标准。
主要发现
- 严重感染总发生率为每100患者年1.09例(95%CI 0.85至1.35)。
- PsA严重感染发生率为每100患者年0.96例(95%CI 0.69至1.28),axSpA为每100患者年1.09例(95%CI 0.76至1.46)。
- 随机对照试验严重感染发生率为每100患者年0.77例(95%CI 0.41至1.20),低于观察性研究的每100患者年1.68例(95%CI 1.03至2.47)。
- PsA患者中IL-12/23抑制剂严重感染发生率最低,为每100患者年0.29例(95%CI 0.00至1.03)。
- 7257例PsA和5638例axSpA患者非严重感染发生率为每100患者年53.0例(95%CI 43.47至63.55);随机对照试验为每100患者年69.95例(95%CI 61.59至78.84),观察性研究为每100患者年15.37例(95%CI 5.11至30.97)。
关键数值与推荐
- 严重感染定义:危及生命、需要静脉抗生素和/或住院治疗的感染。
- 非严重感染定义:不符合严重度标准的感染。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To estimate the incidence of infections among patients with psoriatic arthritis (PsA) or axial spondyloarthritis (axSpA), two distinct phenotypes included in the large group of spondyloarthritis (SpA), treated with tumour necrosis-factor-inhibitors, interleukin-17-inhibitors, Janus kinase-inhibitors, IL-23 or IL-12/23-inhibitors (IL-12/23i), phosphodiesterase 4-inhibitors or cytotoxic T-lymphocyte associated protein 4-Ig. METHODS: A meta-analysis of randomised controlled trials (RCTs), open-label extension and observational studies was conducted. Serious infections were defined as infections that were life-threatening, required intravenous antibiotics and/or hospitalisation. Non-serious infections did not meet these severity criteria. The incidence rates (IR) were reported for each diagnosis by treatment class and study type using random-effect model to create a 95% CI. RESULTS: Among 23 333 PsA patients and 11 457 axSpA patients, there were 1.09 serious infections per 100 patient-years (PY) (95% CI 0.85 to 1.35) with similar IR in PsA (0.96 per 100 PY 95% CI 0.69 to 1.28) and axSpA (1.09 per 100 PY 95% CI 0.76 to 1.46). The IR was lower in RCTs (0.77 per 100 PY 95% CI 0.41 to 1.20) compared with observational studies (1.68 per 100 PY 95% CI 1.03 to 2.47). In PsA patients, the lowest IR value was observed with IL-12/23i (0.29 per 100 PY 95% CI 0.00 to 1.03). There were 53.0 non-serious infections per 100 PY (95% CI 43.47 to 63.55) in 7257 PsA patients and 5638 axSpA patients. The IR was higher in RCTs (69.95 per 100 PY 95% CI 61.59 to 78.84) compared with observational studies (15.37 per 100 PY 95% CI 5.11 to 30.97). CONCLUSION: Serious infections were rare events in RCTs and real-life studies. Non-serious infections were common adverse events, mainly in RCTs. PROSPERO REGISTRATION NUMBER: CRD42020196711.
引用
- Aureal M, Seauve M, Laplane S, et al. Incidence of infections in patients with psoriatic arthritis and axial spondyloarthritis treated with biological or targeted disease-modifying agents: a systematic review and meta-analysis of randomised controlled trials, open-label studies and observational studies. RMD Open. 2023. PMID: 37714666. doi:10.1136/rmdopen-2023-003064
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。